Matinas BioPharma Holdings (MTNB) Depreciation & Amortization (CF) (2013 - 2025)
Matinas BioPharma Holdings (MTNB) posted quarterly Depreciation & Amortization (CF) of $3000.0 for Q4 2025, down 96.67% year-over-year from $90000.0 in Q4 2024, and up 400.0% quarter-over-quarter from -$1000.0 in Q3 2025.
Matinas BioPharma Holdings (MTNB) Depreciation & Amortization (CF) (2013 - 2025) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Depreciation & Amortization (CF) for 13 consecutive years, with $3000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) fell 96.67% year-over-year to $3000.0; the TTM figure through Mar 2026 stood at $14000.0 (down 95.16% YoY), while the FY2025 annual figure was $32000.0, down 91.23% from the prior year.
- Depreciation & Amortization (CF) grew to $3000.0 in Q4 2025 per MTNB's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $98000.0 in Q3 2023 and bottomed at -$1000.0 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $68150.0 across 5 years, with a median of $87500.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 46.87% — and 2025, when it slumped 101.1%.
- Matinas BioPharma Holdings' Depreciation & Amortization (CF) stood at $64579.0 in 2021, then soared by 44.01% to $93000.0 in 2022, then rose by 4.3% to $97000.0 in 2023, then dropped by 7.22% to $90000.0 in 2024, then slumped by 96.67% to $3000.0 in 2025.
- Business Quant data shows MTNB's Depreciation & Amortization (CF) at $3000.0 in Q4 2025, -$1000.0 in Q3 2025, and $12000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Dec 31, 2024 | 90,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Jun 30, 2024 | 90,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Mar 31, 2024 | 94,000.00 |
| Dec 31, 2023 | 97,000.00 |
| Dec 31, 2023 | 97,000.00 |
| Sep 30, 2023 | 98,000.00 |
| Sep 30, 2023 | 98,000.00 |